<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background:Mutations in the Kirsten Ras (KRAS) oncogene are common in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The role of KRAS-mutation status as a prognostic factor, however, is unclear </plain></SENT>
<SENT sid="2" pm="."><plain>We evaluated the relationship between KRAS-mutation status and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> survival, considering <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> in this association by <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> and patient characteristics.Methods:The population-based study included individuals diagnosed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> between 1998-2007 in Western Washington State </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumour</z:e> specimens were tested for KRAS exon 2 mutations, the BRAF p.V600E mutation, and microsatellite instability (MSI) </plain></SENT>
<SENT sid="4" pm="."><plain>We used Cox regression to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association between KRAS-mutation status and disease-specific and overall survival </plain></SENT>
<SENT sid="5" pm="."><plain>Stratified analyses were conducted by age, sex, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> site, stage, and MSI </plain></SENT>
<SENT sid="6" pm="."><plain>We conducted additional analyses combining KRAS-mutation, BRAF-mutation, and MSI status.Results:Among 1989 cases, 31% had KRAS-mutated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Kirsten Ras (KRAS)-mutated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> was associated with poorer disease-specific survival (HR=1.37, 95% CI: 1.13-1.66) </plain></SENT>
<SENT sid="8" pm="."><plain>This association was not evident in cases who presented with distant-stage <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Cases with KRAS-<z:mp ids='MP_0002169'>wild-type</z:mp>/BRAF-<z:mp ids='MP_0002169'>wild-type</z:mp>/MSI-high <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> had the most favourable prognosis; those with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> exhibiting a KRAS- or BRAF-mutation and no MSI had the poorest prognosis </plain></SENT>
<SENT sid="10" pm="."><plain>Patterns were similar for overall survival.Conclusion:Kirsten Ras (KRAS)-mutated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> was associated with statistically significantly poorer survival after diagnosis than KRAS-<z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>.British Journal of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> advance online publication, 19 March 2013; doi:10.1038/bjc.2013.118 www.bjcancer.com </plain></SENT>
</text></document>